Durable complete response to PET-CT driven stereotactic radiation therapy plus pembrolizumab for pleomorphic Pancoast cancer: Case report and literature review.

Castelluccia, Alessandra; Sardaro, Angela; Niccoli Asabella, Artor; Pisani, Antonio Rosario; Rubini, Dino; Portaluri, Maurizio; Tramacere, Francesco

Castelluccia, Alessandra; Sardaro, Angela; Niccoli Asabella, Artor; Pisani, Antonio Rosario; Rubini, Dino; Portaluri, Maurizio; Tramacere, Francesco.

Afiliación

Castelluccia A; Department of Radiotherapy "A. Perrino" Hospital Brindisi Italy.
Sardaro A; Section of Radiology and Radiation Oncology, Interdisciplinary Department of Medicine University of Bari "Aldo Moro" Bari Italy.
Niccoli Asabella A; Section of Nuclear Medicine, Interdisciplinary Department of Medicine University of Bari Aldo Moro Bari Italy.
Pisani AR; Section of Nuclear Medicine, Interdisciplinary Department of Medicine University of Bari Aldo Moro Bari Italy.
Rubini D; Department of Precision Medicine Università degli Studi della Campania Luigi Vanvitelli Napoli Campania Italy.
Portaluri M; Department of Radiotherapy "A. Perrino" Hospital Brindisi Italy.
Tramacere F; Department of Radiotherapy "A. Perrino" Hospital Brindisi Italy.

Clin Case Rep ; 12(4): e8633, 2024 Apr.

Article en En | MEDLINE | ID: mdl-38585585

ABSTRACT

ABSTRACT

PET-driven SBRT plus pembrolizumab as first-line therapy against pleomorphic Pancoast cancer appears beneficial, probably due to high equivalent doses of SBRT on photopenic necrotic core and synergic immune system stimulation of immunoradiotherapy.

Palabras clave

Pancoast tumor; imageguided radiation therapy; immune checkpoint inhibitors; pleomorphic lung cancer; radioimmunotherapy; stereotactic body radiotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google